Good partial responses (Miller Payne grades 3,4) were observed in 32.5% of patients. The remaining 6.5% were poor responders. Seventy-seven patients underwent surgery. The disease-free survival at 1 and 3 years for those who had a pathological complete response was 96.7% and 77.6%, respectively, and 92.3% and 62.7% for those who did not, respectively. The predominant adverse events were hematological, with anemia being the most common one. The addition of cisplatin to neoadjuvant chemotherapy with anthracycline and taxane in TNBC was tolerable and produced a high rate of pathological complete response. Cisplatin added to standard chemotherapy in patients with locally advanced TNBC could improve clinical outcomes.The addition of cisplatin to neoadjuvant chemotherapy with anthracycline and taxane in TNBC was tolerable and produced a high rate of pathological complete response. Cisplatin added to standard chemotherapy in patients with locally advanced TNBC could improve clinical outcomes. Presenting breast cancer symptoms and seeking medical help is a key element in the dia-gnosis and treatment of this disease. Early presentation of symptoms increases the likelihood of recovery. However, some women do not seek medical attention as soon as they find a symptom and delay a visit to the physician. This study is part of a project based on DIPEx qualitative methodology focused on experience of women with breast cancer. The aim of this article is to explore reasons for the delay of the presentation of breast cancer symptoms to a physician. Fifty-three interviews with women were collected across the Czech Republic. Aiming for maximum variation of the sample, the women represent different age groups, education level, marital status, stages of illness and types of treatment. selleck The DIPEx qualitative methodology was used. The first part of the interview is narrative, followed by a semi-structured part. The interviews were verbatim transcribed for the analysis. The data were analysed using NVivo10 software. Open coding was applied from which the categories were constructed and the themes emerged. We used the OSOP (one sheet of paper) method for a thematic analysis. Delay in presenting symptoms to a physician is mainly caused by wrong symptom interpretation, and not considering symptom as serious. In some cases, defence mechanisms are activated and women tend to downplay the symptom. Cognitive distortion is triggered in some women who have experience with such a symptom. Other women tend to prioritize various life events over seeing a physician. Screening tests were perceived positively. Bearing the results in mind, we recommend aiming educational campaigns not only at symptom recognition and the importance of seeking medical help, but also the subsequent steps that need to be taken.Bearing the results in mind, we recommend aiming educational campaigns not only at symptom recognition and the importance of seeking medical help, but also the subsequent steps that need to be taken. Nowadays, modern treatment methods for cancer patients are based on targeting specific molecules involved in cellular signaling system associated with tumor initiation and progression. The success of such approach depends on a correctly chosen dia-gnostic test with high sensitivity that identifies the occurrence and level of bio-markers in patients to select those who will respond and benefit from the treatment. The development of new technologies and the upgrades of the known ones contribute to the innovations in molecular characterization of cancer, which allows the detection of patients mutational status with high sensitivity and specificity. Here, we discuss the utilization of the third-generation type of polymerase chain reaction (PCR), droplet digital PCR (ddPCR), in the molecular dia-gnostics of oncology diseases. According to the studies reported in our review, ddPCR represents a promising tool in genetic profiling of cancer patients. Therefore, the optimization and precise validation may enable gradual implementation of ddPCR into clinical practice in the field of oncology.Here, we discuss the utilization of the third-generation type of polymerase chain reaction (PCR), droplet digital PCR (ddPCR), in the molecular dia-gnostics of oncology diseases. According to the studies reported in our review, ddPCR represents a promising tool in genetic profiling of cancer patients. Therefore, the optimization and precise validation may enable gradual implementation of ddPCR into clinical practice in the field of oncology.Ovarian cancer is one of the most common gynecologic cancers with the highest mortality rate over a long period. Genetic predisposition to ovarian cancer is unusually high. In the Czech Republic, causal mutation in any ovarian cancer predisposition gene is identified in approximately 30% of the ovarian cancer patients. Therefore, according to the current guidelines, all ovarian cancer patients should be provided with genetic testing. The BRCA1 and BRCA2 are the two major ovarian cancer predisposition genes. Nevertheless, mutations in other predisposition genes, including RAD51C and RAD51D, are associated with high ovarian cancer risk. Mutations in RAD51C and RAD51D are found in 1% of ovarian cancer patients in each respective gene. Currently, identification of germline mutation in RAD51C and RAD51D is primarily of preventive importance but it potentially could make a prognostic difference. The aim of this review is to summarize the recent RAD51C and RAD51D knowledge, including the biological function, cancer risks associated with germline mutations, and recommendations for mutation carriers. MicroRNA (miRNA) are a class of short non-coding RNAs that regulate gene expression at the posttranscriptional level. They are involved in key cellular processes and development as well as progression of many diseases. Their levels reflect the physiological state of organisms; therefore, the expression profiles of these molecules are analyzed in bio-marker studies. Due to their properties, miRNA appear to be promising dia-gnostic, prognostic and predictive bio-markers of cancer. Recent studies indicate the existence of sequence variants in miRNA, so-called isomiRs, which differ from the annotated miRNAs by altered sequences due to posttranscriptional modifications. These isomiRs may have a higher abundance than canonical miRNA. The characterization of isomiRs reveals their regulated distribution and different bio-logical properties and thus suggest the possible bio-logical significance of the modifications. The presence of isomiRs can also significantly affect the results of bio-marker studies. Currently, the research is focused on their possible clinical significance.